Iñiguez A, et al. - In a prespecified subgroup (n=456) of patients with multivessel coronary artery disease enrolled in the CENTURY II trial (a prospective, randomized, single-blind, multicenter trial), researchers compared the long-term safety and effectiveness of a sirolimus-eluting stent with bioresorbable polymer (BP-SES; Ultimaster; [n = 225]) to that of a benchmark everolimus-eluting, permanent polymer stent (PP-EES; Xience[(n = 231)]. Low and similar rates of target lesion failure and definite or probable stent thrombosis were reported with both BP-SES and PP-EES at 1 and 5 years. They also found the composite endpoint of cardiac death and myocardial infarction (MI), and patient-oriented composite endpoint of any death, MI, and coronary revascularizations were comparable. Overall, in this high-risk patient population, it was confirmed that the studied bioresorbable polymer stent had good long-term safety and effectiveness.